JP2023539356A5 - - Google Patents
Info
- Publication number
- JP2023539356A5 JP2023539356A5 JP2023514163A JP2023514163A JP2023539356A5 JP 2023539356 A5 JP2023539356 A5 JP 2023539356A5 JP 2023514163 A JP2023514163 A JP 2023514163A JP 2023514163 A JP2023514163 A JP 2023514163A JP 2023539356 A5 JP2023539356 A5 JP 2023539356A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acids
- protein
- modified
- coronavirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063073327P | 2020-09-01 | 2020-09-01 | |
| US63/073,327 | 2020-09-01 | ||
| US202163211716P | 2021-06-17 | 2021-06-17 | |
| US63/211,716 | 2021-06-17 | ||
| PCT/CA2021/051201 WO2022047575A1 (en) | 2020-09-01 | 2021-08-31 | Modified coronavims structural protein |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023539356A JP2023539356A (ja) | 2023-09-13 |
| JP2023539356A5 true JP2023539356A5 (cg-RX-API-DMAC7.html) | 2024-09-17 |
| JP7874621B2 JP7874621B2 (ja) | 2026-06-16 |
Family
ID=80492282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023514163A Active JP7874621B2 (ja) | 2020-09-01 | 2021-08-31 | 改変コロナウイルス構造タンパク質 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240226271A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4208484A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7874621B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230079057A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021335378A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3191257A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL300958A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023002505A (cg-RX-API-DMAC7.html) |
| PY (1) | PY2175039A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202229317A (cg-RX-API-DMAC7.html) |
| UY (1) | UY39400A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022047575A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022322270A1 (en) * | 2021-08-04 | 2024-03-21 | The University Of Melbourne | Vaccine construct and uses thereof |
| CN120957743A (zh) * | 2022-12-16 | 2025-11-14 | 金纽斯生物科技公司 | 多抗原rna sars-cov-2疫苗及相关方法 |
| WO2025106425A1 (en) * | 2023-11-13 | 2025-05-22 | University Of Florida Research Foundation, Incorporated | Immunogenic composition and uses thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI526539B (zh) * | 2010-12-22 | 2016-03-21 | 苜蓿股份有限公司 | 植物中生產類病毒顆粒(vlp)的方法及以該方法生產之vlp |
| WO2018115527A2 (en) * | 2016-12-23 | 2018-06-28 | Curevac Ag | Mers coronavirus vaccine |
-
2021
- 2021-08-31 EP EP21863146.3A patent/EP4208484A4/en active Pending
- 2021-08-31 JP JP2023514163A patent/JP7874621B2/ja active Active
- 2021-08-31 KR KR1020237010167A patent/KR20230079057A/ko active Pending
- 2021-08-31 IL IL300958A patent/IL300958A/en unknown
- 2021-08-31 UY UY0001039400A patent/UY39400A/es not_active Application Discontinuation
- 2021-08-31 MX MX2023002505A patent/MX2023002505A/es unknown
- 2021-08-31 WO PCT/CA2021/051201 patent/WO2022047575A1/en not_active Ceased
- 2021-08-31 US US18/024,140 patent/US20240226271A1/en active Pending
- 2021-08-31 CA CA3191257A patent/CA3191257A1/en active Pending
- 2021-08-31 AU AU2021335378A patent/AU2021335378A1/en active Pending
- 2021-09-01 PY PY202102175039A patent/PY2175039A/es unknown
- 2021-09-01 TW TW110132402A patent/TW202229317A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022279441A1 (en) | Novel multivalent nanoparticle-based vaccines | |
| US20240075125A1 (en) | Expression systems | |
| KR102920353B1 (ko) | 나노입자-기반 인플루엔자 바이러스 백신 및 이의 용도 | |
| EP2536425B1 (en) | Vaccines for use in the prophylaxis and treatment of influenza virus disease | |
| CA2730171C (en) | Soluble recombinant influenza antigens | |
| Phan et al. | ELP ylated haemagglutinins produced in tobacco plants induce potentially neutralizing antibodies against H5N 1 viruses in mice | |
| EP3160501B1 (en) | Influenza virus hemagglutinin protein as a vaccine antigen | |
| JP2013526849A5 (cg-RX-API-DMAC7.html) | ||
| TW201520221A (zh) | 穩定化可溶性融合前rsv f多肽 | |
| JP2012521786A5 (cg-RX-API-DMAC7.html) | ||
| Lin et al. | Glycan masking of hemagglutinin for adenovirus vector and recombinant protein immunizations elicits broadly neutralizing antibodies against H5N1 avian influenza viruses | |
| JP2011527181A5 (cg-RX-API-DMAC7.html) | ||
| Mbewana et al. | Production of H5N1 influenza virus matrix protein 2 ectodomain protein bodies in tobacco plants and in insect cells as a candidate universal influenza vaccine | |
| JP2008524261A5 (cg-RX-API-DMAC7.html) | ||
| EP2956473A1 (en) | Oligomeric influenza immunogenic compositions | |
| CN109966483A (zh) | 一种基于铁蛋白的多抗原通用流感疫苗及其制备方法和应用 | |
| CN118725052A (zh) | 具有稳定融合前构象的呼吸道合胞病毒f蛋白 | |
| WO2024018364A1 (en) | Enveloped virus like particles comprising sars-cov-2 s protein | |
| Karyagina et al. | Development of a platform for producing recombinant protein components of epitope vaccines for the prevention of COVID-19 | |
| WO2009133463A1 (en) | Soluble influenza vaccine | |
| WO2016179099A4 (en) | Modified h7 hemagluttinin glycoprotein of the influenza a/shanghai/2/2013 h7 sequence | |
| Kotlyarov et al. | Development of recombinant vaccine against A (H1N1) 2009 influenza based on virus-like nanoparticles carrying the extracellular domain of M2 protein | |
| KR102259974B1 (ko) | 재조합 항원을 이용하여 목적 항원 특이적인 항체를 제조하는 방법 | |
| Wei | Design and Development of Influenza Neuraminidase Nanoparticle Vaccine | |
| Utomo et al. | An Overview of Recent Developments in the Application of Antigen Displaying Vaccine Platforms: Hints for Future SARS-CoV-2 VLP Vaccines. Vaccines 2023, 11, 1506 |